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Abstract
Mutations in the parkin gene, which encodes a ubiquitin
ligase, are currently recognized as the main contributor to
familial forms of Parkinson’s disease (PD). A simple
assumption about the effects of PD-linked mutations in parkin
is that they impair or ablate the enzyme activity. However, a
number of recent studies, including ours, have indicated that
many disease-linked point mutants of parkin retain substantial
catalytic activity. To understand how the plethora of mutations
on parkin contribute to its dysfunction, we have conducted a
systematic analysis of a significant number of parkin point
mutants (22 in total), which represent the majority of parkin
missense/nonsense mutations reported to date. We found
that more than half of these mutations, including many located
outside of the parkin RING fingers, produce alteration in the
solubility of parkin which influences its detergent extraction
property. This mutation-mediated alteration in parkin solubility
is also associated with its propensity to form intracellular,
aggresome-like, protein aggregates. However, they do not
represent sites where parkin substrates become sequestered.
As protein aggregation sequesters the functional forms away
from their normal sites of action, our results suggest that
alterations in parkin solubility and intracellular localization may
underlie the molecular basis of the loss of function caused by
several of its mutations.
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Parkinson’s disease (PD) is a prevalent neurodegenerative
movement disorder that is characterized by the selective loss
of dopaminergic neurons, and the frequent presence of
ubiquitin-enriched Lewy body inclusions, in the substantia
nigra (Siderowf and Stern 2003). Although the etiology of
PD remains poorly understood, the identiﬁcation of several
key genetic players whose mutations cause rare cases of
familial PD holds tremendous promise for the unravelling of
the molecular pathogenesis of idiopathic PD (Dawson and
Dawson 2003; Lim and Lim 2003). Of the inherited forms of
PD, mutations in the parkin gene are currently recognized as
the main contributor (Kitada et al. 1998; Lucking et al.
2000). Numerous types of parkin mutation, such as missense/
nonsense/frameshift point mutations as well as exon dele-
tions and duplications, cause parkin-related PD (Lucking
et al. 2000; Mata et al. 2004). However, despite their
apparent heterogeneity, there is no discernable difference in
the clinical manifestations among PD patients carrying
different parkin mutations. This suggests that substitutions
of amino acids resulting from missense mutations are as
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detrimental to parkin protein function as are the truncation
and deletion mutations.
Structurally, the parkin protein has a modular organization
consisting of a ubiquitin-like (UBL) domain at its
N-terminus, a RING box domain containing two RING ﬁnger
motifs (termed RING 1 and RING 2) ﬂanking a Cys-rich in-
between RING (IBR) at its C-terminus and a unique middle
segment that links the two domains (Kitada et al. 1998;Morett
and Bork 1999). Several groups have demonstrated that parkin
functions as a ubiquitin ligase associated with the ubiquitin-
proteasome system (UPS), which plays an important role in
maintaining cellular homeostasis through the clearance of
unwanted proteins (Pickart 2001). The RING box domain of
parkin is essential for its catalytic activity (Imai et al. 2000;
Shimura et al. 2000; Zhang et al. 2000). Notably, many
clinically relevant point mutations on parkin occur in this
region (Mata et al. 2004). As protein ubiquitination is usually
linked to proteasomal degradation (Pickart 2001), it is widely
speculated that the absence of functional parkin would lead to
the toxic accumulation of its substrates within susceptible
neurons, eventually leading to their demise. Consistent with
this hypothesis are the observations that numerous reported
substrates of parkin accumulate in brains of PD patients
carrying parkin mutations (Imai et al. 2001; Shimura et al.
2001; Staropoli et al. 2003). Several other reports have also
implicated neuroprotective roles of parkin in response to
diverse cellular insults including a-synuclein toxicity, protea-
somal dysfunction, unfolded protein stress and kainate-
induced excitotoxicity (Feany and Pallanck 2003). Taking all
these ﬁndings together, it thus seems reasonable to assume that
the catalytic activity of parkin is required for the proper
maintenance of dopaminergic neuronal function. However, a
number of recent studies, including ours, have indicated that
many disease-linked point mutants of parkin retain substantial
catalytic activity (Imai et al. 2000; Zhang et al. 2000; Chung
et al. 2001; Gu et al. 2003). Clearly, catalytic impairment of
parkin cannot be the sole contributor to parkin dysfunction.
To understand how the plethora of reported mutations on
parkin contribute to its dysfunction and result in a common
pathogenic outcome, we have conducted an analysis of a large
number of parkin point mutants (22 in total), which represent
the majority of parkin missense/nonsense point mutations
reported to date (Mata et al. 2004). We ﬁnd that many of these
parkin mutations produce alterations in protein solubility and
localization within the cell. Further, the mislocalized parkin
mutants form aggresome-like structures (Kopito 2000), which
stain positively with ubiquitin and c-tubulin.
Materials and methods
cDNAs, Antibodies and Reagents
Myc-tagged synphilin-1, CDCrel-1 and synuclein cDNAs have
previously been described (Zhang et al. 2000; Chung et al. 2001).
The FLAG-tagged parkin expression construct was a kind gift from
R. Takahashi. All the parkin missense mutants described in this
report were generated by means of PCR site-directed mutagenesis
using FLAG-tagged parkin cDNA as a template. The mutagenesis
reactions were based on the QuickChangeTM method (Stratagene,
La Jolla, CA, USA). The various parkin mutant constructs were
completely sequenced to ensure that they contain only the
introduced mutations. Lactacystin was purchased from Afﬁniti-
Research. All other chemicals were purchased from Sigma (St
Louis, MO, USA). The following antibodies were used: Monoclonal
and rabbit polyclonal anti-Flag (Sigma), monoclonal anti-myc
(Roche), monoclonal anti-b actin (Sigma), rabbit polyclonal anti-
ubiquitin (Dako A/S, Glostrup, Denmark), antic-tubulin (Sigma),
Fluorescein-conjugated anti-mouse or anti-rabbit IgG (Jackson
ImmunoResearch), Rhodamine-conjugated antimouse or anti rabbit
IgG (Molecular Probes). Typically, antibodies were used at a
concentration of 0.2 lg/mL for immunoblotting and 0.1 lg/mL for
immunocytochemistry.
Cell Culture, Transfections, Preparation of Cell Lysates and
Western Blot Analysis
Human Embryonic Kidney (HEK) 293 cells and SH-SY5Y cells
were grown in DMEM containing 10% FBS in a 5% CO2
atmosphere. Cells were transiently transfected with various expres-
sion vectors using LipofectAMINE PLUS reagent (Invitrogen,
Carlsbad, CA, USA) according to the manufacturer’s instructions.
Two days later, transfected cells were lysed in PBST buffer
containing 1% Triton X-100, 10 lg/mL aprotinin and 1 mM PMSF
in PBS and sedimented at 125, 000 g for 30 mins at 4C.
Supernatants from the initial fractionation were saved as the Triton-
X-soluble fractions (S), and the pellets were washed once with
PBST buffer before re-extraction with SDS buffer (PBST containing
1% SDS in place of Triton X-100). After sedimentation at 125 000 g
for 30 mins at 4C, the supernatants were saved as the SDS fractions
(P). For some experiments, an intermediate strength extraction
buffer (RIPA) containing 50 mM Tris, pH 8, 150 mM NaCl, 0.1%
SDS, 0.5% sodium deoxycholate and 1% Nonidet P-40 was used in
between the S and P extractions. Equivalent amount of proteins
among different S and P fractions were resolved by means of SDS–
PAGE and the levels of various ectopically expressed proteins were
analyzed by means of western blotting procedures using ECL
detection reagents (Amersham, Little Chalfont, Buckinghamshire,
UK). In our initial expression studies, the proteasome inhibitor
lactacystin was used to rule out that some poorly expressing parkin
mutants is due to their rapid degradation by the ubiquitin-
proteasome system. In these studies, transfected cells were treated
with 5 lM clasto-lactacystin b-lactone at 24 h post-transfection for
an additional 24 h.
Immunocytochemistry and Confocal Microscopy
5 · 104 HEK 293 or SH-SY5Y cells were seeded onto polylysine
coated sterile glass coverslips in a 24-well culture plate a day prior
to transfection. After attachment, cells were transfected as described
above with 0.25 lg of the appropriate constructs. Two days later,
cells were washed once with PBS and ﬁxed in 3% paraformaldehyde
(w/v) for 20 min. The ﬁxed cells were washed three times with PBS
before permeabilzation in 0.2% (v/v) Triton X-100 in PBS for
5 min. Blocking was then carried out with 5% goat serum in PBS
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for 1 h. This was followed by incubation in primary antibodies for 1
h at 25C and secondary antibodies for another hour at 25C.
Immunoﬂuorescent images were acquired on an Olympus confocal
microscope. Negative controls omitting each primary antibody were
performed in each case and no signiﬁcant staining was seen (data
not shown). To determine the number of cells containing aggregates,
at least 100 FLAG-parkin positive cells were examined and counted
from each of the three independent wells per experiment. Cells were
counted in a blinded manner and quantitative results reported are an
average of at least 3 experiments. Statistical signiﬁcance was
determined using Student’s paired t-test for all comparisons.
Results
A large number of familial PD-linked point mutations on
parkin influence its solubility in cells
Our initial expression studies of the parkin point mutants in
HEK 293 cells indicated that most of these mutants, except
for A82E, M192L, K211N, T240R, T415N, G430D and
P437L are expressed poorly relative to wild-type parkin
(Fig. 1). We reasoned at ﬁrst that the poor expression level of
the majority of parkin mutants examined could be due to
their rapid degradation via the UPS. However, treating cells
transfected with several poorly expressing species of parkin
mutants with the proteasome inhibitor, lactacystin, did not
signiﬁcantly improve their subsequent detection by means of
western blot (data not shown). As we were examining the
expression of parkin in transfected cell extracts prepared
using a mild detergent (Triton-X-100), we reasoned that any
alteration of parkin solubility by its mutations could inﬂu-
ence its protein extraction property and hence, its detection
under our experimental conditions. To address this possibility,
we performed sequential extraction of the transfected cells
with Triton-X-100 and SDS, respectively, to examine the
population of parkin in both the Triton-X-100-soluble (S)
and -insoluble (P) fractions. Interestingly, we found that
transfected wild-type parkin resides in both fractions. The
extraction proﬁle of parkin mutants that ‘expressed well’,
including A82E, M192L, K211N, T240R, T415N, G430D
and P437L, are essentially similar to that of wild-type parkin.
However, all the other mutants that are barely detectable in
the S-fractions show robust immunoreactivities in the
P-fractions (Fig. 1). Further, the expression levels of these
mutants compare well to wild-type parkin in the P-fraction.
Although the relative ratio of expression of three mutants,
R42P, C268X and Q311X, to wild-type parkin remains low
in the SDS-pool, they nonetheless represent a signiﬁcant
increase over their respective Triton-X-100-pool (Fig. 1).
Apparently, the ‘poorly expressed’ mutants are preferentially
localized to an intracellular location that is resistant to Triton-
X-100 extraction. In examining the extraction proﬁle of the
various parkin species, we also noticed that many of them
show the presence of high molecular weight complexes that
are particularly evident in the P-fractions. This is consistent
with previous studies conducted by others with FLAG-
tagged parkin (Imai et al. 2000; Junn et al. 2002). The high
molecular weight parkin smears we observed possibly
represent ubiquitinated parkin species.
To dissect the differential extractibility of the various
parkin mutants ectopically expressed in HEK 293 cells
further, we repeated our serial extraction experiments with a
more elaborate set of buffers: PBS; PBS + 1% Triton-X-100
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Fig. 1 Biochemical distribution of wild-type
parkin and various parkin mutants in trans-
fected cells. (a) Schematic figure of parkin
illustrating the positions of the various point
mutations of parkin constructs used in this
study. (b) Representative anti-FLAG
immunoblots of cell extracts sequentially
prepared with Triton-X-100 (S) and SDS (P)
from HEK 293 cells transfected either with
wild-type parkin or various parkin mutants
(as indicated). The blots were stripped and
reprobed with anti-actin antibody to reflect
loading variations. The experiment was
repeated 3 times with similar results.
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(PBST); RIPA and PBS + 1% SDS (SDS), that cover a
broader range of extraction strength. We found that the
Triton-X-100 soluble parkin species are easily extractable by
sonicating the transfected cell pellet with PBS alone, while
the Triton-X-100-insoluble species remain insoluble in all the
extraction buffers except the one containing 1% SDS
(Figs 2a,b). Presumably, the Triton-X-100 soluble forms of
parkin reside freely in the cytosol while the Triton-X-100-
resistant forms of parkin protein exist as protein aggregates.
We also expressed a subset of parkin mutants in SH-SY5Y
neuroblastoma cells to see if their respective extraction
proﬁle observed earlier is similar in a different cell line. As
shown in Fig. 2(c), the extraction properties of these mutants
remain unchanged when expressed in the neuroblastoma cell
line. Taken together, our results suggest that a large number
of familial PD-associated point mutations on parkin result in
altered solubility of the protein and as such, inﬂuence its
detergent extraction property.
Parkin mutants with altered solubility have a propensity
to form aggresome-like structures in cells
We were curious to know whether the mutation-mediated
alteration in the solubility of parkin affects the intracellular
distribution of the protein. To examine this, we transfected
each of our parkin mutants into SH-SY5Y cells. Consistent
with previous reports by others (Cookson et al. 2003; Gu
et al. 2003), we found that normal parkin is uniformly
expressed throughout the cytoplasm in the majority of the
transfected cells (Fig. 3a). Mutants that share similar extrac-
tion property to wild-type parkin (A82E, M192L, K211N,
T240R, T415N, G430D and P437L), are localized in the
same fashion as wild-type parkin within the transfected cells
(Fig. 3a). Although occasional parkin-immunoreactive
aggregates occur in these cells, they account for fewer than
4% of the population of transfected cells (Fig. 3c). However,
among the mutants that are predominantly found in the
Triton-X-100 insoluble pellet, about 75% show a propensity
to form intracellular protein aggregates (Fig. 3b). On aver-
age, the occurrence of parkin-immunoreactive aggregates in
cells transfected with these detergent-resistant mutants is
about 30%, but some mutants like C289G and C441R
formed aggregates in as much as 60% of the transfected cells
(Fig. 3c). There is however, no absolute correlation between
the extent of detergent insolubility of the parkin mutants and
the number of inclusions formed (data not shown). Notably,
many of these parkin mutant-mediated aggregates tend to
concentrate into a single, mostly perinuclear, mass that is
reminiscent of the aggresome, a centriole-associated structure
(Kopito 2000) (Fig. 3b).
To further explore the potential centrosomal recruitment of
parkin mutant-mediated aggregates, we transfected SH-
SY5Y cells with a subset of parkin mutants (C268X,
R275W, C289G, C441R) that showed the highest tendency
to form intracelluar aggregates and costained the cells with
parkin and c-tubulin, a centrosome marker. We observe that
the major perinuclear aggregate formed by each mutant
colocalized with c-tubulin. Further, these perinuclear aggre-














































































































Fig. 2 Differential extractibility of various parkin mutants. (a) Anti-
FLAG immunoblots of cell extracts sequentially prepared with PBS
and PBS + 1% Triton-X-100 (PBST) from HEK 293 cells transfected
either with wild-type parkin or parkin mutants that are readily extract-
able with PBST. (b) Anti-FLAG immunoblots of cell extracts sequen-
tially prepared with PBST, RIPA and SDS buffers from HEK 293 cells
transfected either with wild-type parkin or parkin mutants that are not
readily extractable with PBST. (c) Anti-FLAG immunoblots of cell
extracts sequentially prepared with PBST (S) and SDS (P) from
SH-SY5Y cells transfected either with wild-type parkin or a subset of
parkin mutants (as indicated). The various blots were stripped and
reprobed with anti-actin antibody to reflect loading variations. These
results were replicated 3 times.
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shown for R275W and C289G mutants). Expectedly, treat-
ment of the cells with nocodozole, a microtubule depolym-
erizing agent, led to the dispersion of the perinuclear
aggregates into multiple smaller aggregates scattered
throughout the cytoplasm (Fig. 4c; data not shown for
R275W and C289G mutants). Thus, parkin mutant-mediated
aggregates appear to resemble an aggresome, an observation
that is consistent with previous demonstration by others that
the R275W and C289G formed aggresome-like structures
when overexpressed in cells (Cookson et al. 2003; Gu et al.
2003). Taken together, these results suggest that mutations on
parkin that decrease its solubility tend to affect the cellular
distribution of the protein, leading to the formation of
aggresome-like structures within the cell.
The parkin substrates CDCrel-1 and Synphilin-1 are
not sequestered within the parkin-mutant mediated
aggregates
Mutations of parkin could affect its enzyme activity by
abolishing its recruitment of its substrates or cognate E2s, or
both. Hence, a catalytically impaired parkin retains the
potential to bind substrate. Indeed, our previous reports
indicate that some familial-linked PD mutations of parkin do
not signiﬁcantly abolish the ability of parkin to recruit its
substrates, CDCrel-1 and Synphilin-1 (Zhang et al. 2000;
Chung et al. 2001). We were therefore curious to know if
these substrates of parkin are bound to the parkin mutant-
mediated aggregates. To address this possibility, we
expressed either CDCrel-1 or Synphilin-1 in SH-SY5Y cell
(a) 
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Fig. 3 Localization of parkin mutants in transfected SH-SY5Y cells.
SH-SY5Y cells were transfected with various FLAG-tagged parkin
constructs (as indicated) and stained for exogenously expressed
parkin using anti-FLAG antibody (red). (a) Vector transfected cells
showed no background staining whereas transfection with either wild-
type parkin or Triton-X-100 soluble parkin mutants showed uniform
cytoplasmic staining. (b) Triton-X-100 insoluble parkin mutants
expressed in SH-SY5Y cells tend to form inclusion-like structures that
accumulate around the perinucleus (arrows) (c) Graph showing the
percentage of cells containing anti-FLAG-positive aggregates. Bars
shown are the means from at least 3 independent experiments, and
the error bars indicate the mean ± SE. Statistical variance, whenever
significant, are indicated (*p < 0.01; **p < 0.001, Student’s t-test).
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in the presence of wild-type parkin or the parkin mutants,
A82E, which does not form inclusions, C268X, R275W,
C289G or C441R, which have the highest propensities to
form protein inclusions. As the major form of a-synuclein
does not interact with parkin, but is nonetheless a major
component of Lewy body, we also coexpressed a-synuclein
with each of these parkin species. Examination of the various
transfected cells reveals that CDCrel-1, Synphilin-1 and
a-synuclein, like parkin, are homogeneously distributed in
the cytoplasm. Hence, all of these proteins overlap with the
evenly distributed wild type parkin and the A82E mutant
(Fig. 5, Supplementary Figure S1). While a-synuclein does
not colocalize with any of the parkin mutant-mediated
aggregates, neither CDCrel-1 nor Synphilin-1 is recruited to
these aggregates (Fig. 5, Supplementary Figure S1). Hence,
aggregates formed by parkin mutants in these cases do not
appear to represent sites within which its substrates are
sequestered.
Discussion
To date, numerous biochemical studies aimed at under-
standing how familial PD-associated point mutations in
parkin affects its function have been conducted. Although
informative, the ﬁndings from these studies require careful
interpretation as they are often derived from the character-
ization of a limited number of parkin mutants. For example,
two recent studies utilizing 4–5 parkin point mutants
demonstrated that mutations in parkin occuring at either
RING 1 or 2 results in altered intracellular localization of
the protein (Cookson et al. 2003; Gu et al. 2003). Here, we
report the characterization of 22 clinically relevant parkin
point mutants that represent the majority of parkin missense
and nonsense mutations reported to date. We found that
more than half of these parkin mutants, including many that
do not reside within parkin RING ﬁngers, produce altera-
tions in the solubility of the proteins and result in their
aggregation within the cell. We further show that the
mutant-mediated aggregates share features of an aggresome,
but do not represent sites within which parkin substrates
such as CDCrel-1 and Synphilin-1 are sequestered. Based
on their respective detergent extractibility and tendency to
form intracellular aggregates, we can broadly categorize the
parkin point mutants examined into three groups: I –
soluble; II – insoluble with low propensity to form
inclusions; and III – insoluble with high propensity to
form inclusions (Fig. 6).
While parkin-mediated inclusion formation has been
initially reported by Junn et al. (2002) and subsequently by
other investigators, signiﬁcant inclusion formation by parkin
in these studies only take place in the presence of protea-
somal impairment (Junn et al. 2002; Ardley et al. 2003;
Zhao et al. 2003). Consistent with these studies, we did not
observe a propensity for wild-type parkin to form inclusion
under basal conditions. It is therefore interesting for us to
note in our present study that several parkin mutations
located at various lengths of the protein could produce
inclusions in the absence of exogenously added proteasome
inhibitors. However, we cannot rule out at this moment that
the overexpression of these inclusion-forming mutants could
compromise proteasomal activity, and thereby promoting
their aggregation. It remain curious to us why the Group I




Fig. 4 Parkin mutant-mediated inclusions resemble aggresomes. (a)
SH-SY5Y cells transfected with the following FLAG-tagged parkin
mutants, C268X and C441R, were coimmunostained with anti-ubiqu-
itin (red) and anti-FLAG (green) antibodies. The merged pictures show
colocalization of the anti-ubiquitin and anti-FLAG staining (yellow). (b)
As in (a) except that coimmunostaining of cells were performed with
anti-c-tubulin (red) and anti-FLAG (green). The merged pictures in this
case show colocalization of the anti-c-tubulin and anti-FLAG staining
(yellow). (c) Merged pictures showing the dispersion of the anti-c-
tubulin/anti-FLAG-immunopositive aggregates (yellow) in transfected
cells treated with 2 lg/mL nocodozole. These results were replicated 3
times.
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extractable with Triton-X-100 have a low propensity to
aggregate within the cell despite also having a signiﬁcant
population represented in the detergent-insoluble pool. We
are similarly intrigued by the low tendencies of Group II
parkin mutants to generate intracellular inclusions. Presum-
ably, the degree of misfolding among different parkin
mutants, as discussed later, contributes to their relative
propensities to form protein inclusion. Although our study
presented here is in general agreement with several previous
reports by others, there are some differences relating to the
expression proﬁle and inclusion forming ability of a few
mutants (Table S1). In such cases, we thought that differ-
ences in the extraction methodology, choice of cell line or
epitope tag may be the reasons for our conﬂicting observa-
tions. To address this, we have generated several myc-tagged
parkin mutants and expressed them in SH-SY5Y cells but
found that both the myc-tagged and FLAG-tagged versions
of our mutants behave similarly in terms of their detergent
extraction and inclusion formation properties (data not
shown). We have also repeated our localization studies in










Fig. 5 The parkin substrates CDCrel-1 and Synphilin-1 are not
sequestered within parkin mutant-mediated aggregates. SH-SY5Y
cells were cotransfected with various FLAG-tagged parkin species and
the following myc-tagged constructs: (a) CDCrel-1 and (b) Synphilin-1.
Cells were coimmunostained with anti-myc (green) and anti-FLAG
(red). The merged pictures in each case show colocalization of the
anti-myc and anti-FLAG staining (yellow). Where inclusions are ob-
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Fig. 6 Categorization of parkin mutants. Based on their respective
detergent extractibility and their propensity to form intracellular
aggregates, the parkin mutants examined can be categorized into 3
groups: Group I – Soluble; II – Insoluble with low tendency to form
inclusions; and III – Insoluble with high tendency to form inclusions. S
and P fractions refer to Triton-X-100 and SDS extractable fractions,
respectively.
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normal and mutant parkin species consistent with their
detergent extraction properties, except that the tendency of
some mutants (R42P, R256C, C212Y and C431F) to form
inclusion becomes less pronounced in HEK293 cells com-
pared to SH-SY5Y cells (data not shown). Hence, the choice
of cell lines used does appear to be important in the case of
these selected mutants and may account for the discrepancies
among different studies.
Several reports have indicated that many disease-linked
point mutants of parkin retain substantial catalytic activity,
suggesting that mutations in parkin do not always produce a
simple loss of function (Chung et al. 2001; Gu et al. 2003).
Our observation that a large group of parkin mutants (Group
III, Fig. 6) have a tendency to become aggregated suggest
that protein misfolding may underlie the molecular basis of
the loss of parkin function caused by these parkin mutations.
Notably, all the four nonsense mutations in parkin we
examined belongs to this group. These mutants, which are
truncated at various lengths from the C-terminus of the
protein, are presumably folded incorrectly due to large
structural changes associated with their truncations. As a
result, they probably tend to exist as detergent-insoluble
aggregates. Indeed, the inclusion-forming W453X parkin
mutant has been recently demonstrated to adopt a misfolded
conformation spontaneously (Winklhofer et al. 2003). In this
case, the deletion of only three C-terminal amino acids of
parkin is sufﬁcient to induce a detergent-insoluble confor-
mation. Hence, the larger deletion of parkin C-terminus
associated with the C268X, Q311X and E409X mutants
would be expected to produce a similar, if not a more
pronounced, alteration in parkin structure. Since the catalyt-
ically essential RING box is partially or totally missing in
these mutants, it is also easy to understand why these mutants
would also be non-functional. Interestingly, many missense
parkin mutants containing just one amino-acid substitution
behave in the same manner to these truncation mutants in
terms of their detergent extractibility and intracellular
localization. A simple yet logical explanation to why a
single mutation on parkin could mirror the same effect
brought about by large region of truncation is that the
residues affected in these mutants are absolutely critical in
maintaining the native structure of parkin. Consistent with
this notion are our observations that, detergent-resistant
aggregates occur in all the three parkin mutants examined
that contain mutations affecting the RING-cysteine residues.
These highly conserved cysteine residues deﬁne the structure
and function of a RING ﬁnger and their mutations are
expected to alter the RING conformation tremendously
(Morett and Bork 1999; Zheng et al. 2000). Presumably, the
other important residues affected act in similar ways.
However, we cannot completely exclude the possibility that
the altered biochemical properties of parkin mutants could be
due to changes in their interaction with other proteins or
other cellular components, such as membranes. Undoubtedly,
structural studies of the various parkin mutants would
provide helpful insights into their relative conformational
changes.
It is conceivable that the aggregation of parkin would
sequester the protein away from its normal site of action and
as a result, deplete the cell of its soluble pool of functional
parkin. Thus, despite being reported to be catalytically active,
the aggregation-prone R275W mutant may not have enough
soluble forms in the cell to cope with the protein load
normally handled efﬁciently by wild-type parkin. The same
situation probably applies to parkin mutants sharing similar
properties to the R275W mutant. As functional parkin has
been shown to fulﬁl multiple neuroprotective roles (Feany
and Pallanck 2003), its depletion in the cell as a result of
rapid aggregation would be expected to increase the
susceptibility of the cell to apoptosis following insults. Our
speculation is in agreement with emerging evidence indica-
ting that parkin haploinsufﬁciency, as well as parkin
promoter variability, are associated with the development
of PD and the ensuing hypothesis that the expression level of
parkin is important in maintaining neuronal surviability
(West et al. 2002a,b; Foroud et al. 2003).
A very intriguing feature of parkin-proven PD cases is the
apparent lack of Lewy bodies (LBs) reported in a number of,
albeit limited (< 8), detailed pathological examinations (Mata
et al. 2004). This has led to the popular speculation that
functional parkin is required for the formation of LBs.
However, alternate pathologies describing the presence of
tau-positive inclusion (3 cases) andLBs (1 case) have also been
reported (Farrer et al. 2001; Mata et al. 2004). The latter case
occurs in a patient with a null mutation in one parkin allele and
a R275W substitution in another (Farrer et al. 2001). Since the
R275W retain catalytic activity (Chung et al. 2001) and at the
same time has a propensity to become aggregated, our results
may help explain the alternate pathology observed. It is
tempting to speculate that the other aggregation-prone Group
III mutants may also be associated LB formation. Indeed, the
aggregates mediated by this group of parkin mutants appear to
be aggresome-like and may represent a precursor to LB.
Curiously, although a-synuclein is a major constituent of LBs,
we were not able to detect its recruitment into aggresomes
mediated by the parkin mutant overexpression. Our result is
however, consistent with the report by Muqit et al. describing
the absence of a-synuclein immunoreactivities in parkin-
positive aggresomes (Muqit et al. 2004). Likewise, a-synuc-
lein is absent in aggregates induced by proteasome inhibition
(Paxinou et al. 2001). Although the R275Wmutant-mediated
inclusion overlapped with the distribution of endogenous
a-synuclein in the study conducted by Cookson et al. there
was no speciﬁc recruitment of a-synuclein into aggresome
(Cookson et al. 2003). However, some investigators were able
to detect a-synuclein in aggresomes (Junn et al. 2002; Lee
et al. 2002). At this moment, we do not know if the
inconsistencies are due to differences in cell lines and
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antibodies used, or they reﬂect the limitations of cell culture
system in recapitulating in vivo events accurately. Similar to
our observation with a-synuclein, neither synphilin-1 or
CDCrel-1 is recruited into the parkin mutant-mediated aggre-
gates. Whereas the occurrence of CDCrel-1 in Lewy body
remains to be established, synphilin-1, like a-synuclein, is a
known component of LB (Wakabayashi et al. 2000). It is
conceivable that the biogenesis of LBs in dopaminergic
neurons in vivo requires the participation of multiple players
and conditions that are not present in our cell culture models.
Nonetheless, the propensity of the Group III parkin mutants to
form aggregates within cells suggests that their capabilities of
mediating inclusion formation in vivo may ultimately culmin-
ate into LBs.
In summary, we demonstrate here that numerous mutations
occuring at different regions of the parkin protein could exert
profound effects on its structural integrity, resulting in its
aggregation. The subsequent depletion of the cytoplasmic
pool of soluble parkin may underlie the molecular basis of
the loss of function in these mutants. Although the molecular
mechanisms underlying the loss of function in Group I & II
parkin mutants (Fig. 6) remain to be determined, we believe
that mutations in these two groups of mutants are likely to
directly affect the interaction between parkin and its import-
ant cellular partners. However, it remains a challenge to
understand how parkin mutants with distinctly different
biochemical properties perturb cellular pathways that even-
tually converge into the same ﬁnal pathogenic outcome.
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